1. HER2 blockade in metastatic collecting duct carcinoma (CDC) of the kidney: a case report.
- Author
-
Bronchud MH, Castillo S, Escriva de Romaní S, Mourelo S, Fernández A, Baena C, Murillo J, Julia JC, Esquius J, Romero R, and Andreu X
- Subjects
- Administration, Oral, Aged, Antibodies, Monoclonal, Humanized administration & dosage, Capecitabine, Carcinoma, Renal Cell pathology, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Fluorouracil administration & dosage, Fluorouracil analogs & derivatives, Humans, Injections, Intravenous, Kidney Neoplasms pathology, Lapatinib, Male, Quinazolines administration & dosage, Trastuzumab, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Brain Neoplasms prevention & control, Brain Neoplasms secondary, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell secondary, Kidney Neoplasms drug therapy, Receptor, ErbB-2 antagonists & inhibitors
- Abstract
Background: Collecting duct carcinoma of the kidney (CDC) is a rare cancer associated with bad prognosis and, at present, with no specific effective therapies., Case Report: We report a clinical case with disseminated highgrade CDC presenting with widespread metastasis to both lungs, pelvic bones, axial skeleton, and the central nervous system (posterior fossa, both hemispheres and pituitary-hypothalamic). The primary tumor in the kidney was demonstrated (by fluorescence in situ hybridization and immunohistochemistry with Herceptest (3+ score)) to significantly overexpress HER2. Critically ill at presentation, the patient received oral capecitabine together with double HER2 blockade with both intravenous trastuzumab and oral lapatinib. His clinical response was a dramatic improvement and a progressive decline in the radiological size of all of his multiple cancer lesions., Conclusion: Double HER2 blockade is an effective therapy in disseminated CDC even in the presence of brain metastases.
- Published
- 2012
- Full Text
- View/download PDF